Monthly Archives: July 2013

The People Side of Biotech Deal-Making
July 24, 2013

Getting deals done with Pharma is critical to the strategy of many Biotech companies.  Pharma deals often offer less dilutive funding to advance a program or portfolio, market validation enabling future traction, and potentially important liquidity for shareholders.  Given their

5 Comments

A View Through An Open Window For Biotech IPOs
July 9, 2013

For the first time in over a decade, there’s real talk about an open IPO window for biotech companies.  The NVCA’s second quarter update highlighted that venture-backed biotech outpaced all other industry sectors in the number of IPOs and the

Leave a comment